TITLE

Cost Comparison of Psoriasis Treatments

AUTHOR(S)
Mikhael, Dalia; Babcock, Kelly; DesGroseilliers, Jean-Pierre
PUB. DATE
November 2009
SOURCE
Journal of Cutaneous Medicine & Surgery;Nov/Dec2009, Vol. 13 Issue 6, p303
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Knowledge of the cost of various psoriasis therapeutic options is essential to the prescribing clinician. Objective: To compare the cost of various psoriasis treatments over a 10-year period in the province of Ontario, Canada. Methods: We used a hypothetical patient with plaque-type psoriasis of moderate severity with a Psoriasis Area and Severity Index of 10, body surface area of 20%, and no joint involvement. The costs to treat this hypothetical patient with different therapeutic regimens were compared in this study. Results: In a 60 kg patient, alefacept was the most costly form of therapy, based on two 12-week treatments per year, followed by infliximab 5 mg/kg. In a 90 kg patient, infliximab 5 mg/kg was the most costly, followed by alefacept. The least costly treatment was ultraviolet B phototherapy. Conclusion: With the knowledge of these data, informed prescribing by the dermatologist may reduce the financial burden to the patient, the provincial health care system, and insurance companies
ACCESSION #
91707117

 

Related Articles

  • Could mycophenolate mofetil play a role in treatment of recalcitrant psoriasis? Newman, Laura // Dermatology Times;Nov96 Supplement Psoriasis, Vol. 17 Issue 11, pS6 

    Examines the efficacy of mycophenolate mofetil (MMF) in the treatment of psoriasis. Characteristics; Possibility of immunosuppressive side effects; Comparison of bioavailability with mycophenolic acid; Cost of treatment.

  • Price Tag Holds Back Biologics for Psoriasis. Nash, Karen // Dermatology Times;Apr2003, Vol. 24 Issue 4, p14 

    Comments on the use of biologics to treat psoriasis in the U.S. Details on the side-effects of the drug; Impact of the high-cost treatment on patient compliance; Action of biologics in comparison with the traditional way of curing psoriasis.

  • new drugs for psoriasis might be lifesavers. Steinmehl, Eric; Martin, Adam // Health (Time Inc. Health);Mar2004, Vol. 18 Issue 2, p68 

    Provides information on biologics, a drug for treating psoriasis. Annual cost of the treatment; Percentage of people with psoriasis who consider committing suicide; Description of psoriasis.

  • Generalized pustular psoriasis: strategy for identification of psoriasis susceptibility gene. Muto, Masahiko; Ohmura, Akiko; Hamamoto, Yoshiaki; Konishi, Yoshitake; Shiozawa, Shunichi; Youn, Jai Il; Tanifuji, Junji; Furuya, Kazuhiko; Sasazuki, Takehiko; Ogawa, Hideoki // Archives of Dermatological Research;Apr2003 Supplement 1, Vol. 295, pS60 

    Discusses the genetic aspects of generalized pustular psoriasis in comparison with genetic aspects of psoriasis vulgaris. Manifestations of the disease; Treatment for generalized pustular psoriasis; Relevance of human leukocyte antigen with von Zumbusch-type generalized pustular psoriasis.

  • 11. Psoriasis, Acne, etc.  // Journal of Cutaneous Medicine & Surgery;Jun2005, Vol. 9 Issue 3, p147 

    The article discusses several research being done on psoriasis. It references studies including an examination a psoriasis lesions for production of interleukin-23 by E. Lee, W. L. Trepicchio, J. L. Oestreicher et al published in the 2004 issue of "Journal of Experimental Medicine" and a...

  • Costs similar for methotrexate, ciclosporin in plaque psoriasis.  // PharmacoEconomics & Outcomes News;8/14/2004, Issue 459, p8 

    Discusses research being done on the costs associated with methotrexate and ciclosporin treatment among patients with plaque psoriasis. Reference to a study by B. C. Opmeer, et al published in the June 2004 issue of "Archives of Dermatology"; Outcomes after 16 weeks of treatment; Comparison of...

  • Efalizumab and etanercept cost-effective choices in psoriasis.  // PharmacoEconomics & Outcomes News;6/4/2005, Issue 479, p11 

    Discusses research being done on biologics for the treatment of psoriasis. Reference to a study by K. Ramos et al, published in April 2005 of the "Journal of Managed Care Pharmacy"; Analysis of the effectiveness of efalizumab and etanercept in treating the disease; Comparison between the...

  • Infliximab good value for money in psoriasis.  // PharmacoEconomics & Outcomes News;1/24/2009, Issue 570, p6 

    The article discusses a study on the cost effectiveness of biologics for psoriasis from the perspective of the Swiss healthcare system. It showed that the use of infliximab is potentially cost effective in the treatment of psoriasis. The regimes compared in the study are infliximab, etanercept,...

  • Calcipotriene plus topical steroids may outshine steroid use alone for psoriatic patients. Meszaros, Liz // Dermatology Times;Nov96 Supplement Psoriasis, Vol. 17 Issue 11, pS15 

    Examines the efficacy of combined calcipotriene and topical steroids as psoriasis treatment. Significant reduction of psoriasis within 2 weeks; Prevention of side effects; Efficacy comparison of calcipotriene with fluocinocide.

  • Topical corticosteroids and relapses of psoriasis.  // British Medical Journal;4/16/1977, Vol. 1 Issue 6067, p988 

    Examines the efficacy of topical corticosteroids in patients with psoriasis. Treatment duration and remission; Comparison of healing rates; Concerns on the side effects with long term treatment.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics